Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 227

The DOI matches its Crossref record.

Long-term Outcome of Treatment with Intravenous Cyclosporin in Patients With Severe Ulcerative Colitis

Arts, Joris, D’Haens, Geert, Zeegers, Miranda, Van Assche, Gert, Hiele, Martin, D’Hoore, André, Penninckx, Freddy, Vermeire, Severine, Rutgeerts, Paul · 2004 · Inflammatory Bowel Diseases

Abstract

OBJECTIVES: Iv cyclosporin A (CSA) is an effective therapy in patients with severe ulcerative colitis (UC). It remains unclear if this treatment affects the course of the disease in the long run. We investigated the long-term efficacy and safety in 86 patients with ulcerative colitis treated with i.v. CSA at our center. METHODS: The records of all patients treated with i.v. CSA between 11/1992 and 11/2000 were reviewed. RESULTS: Seventy-two of 86 patients (83.7%) responded to i.v. CSA therapy, administered for a mean of 9 +/- 2 days. Following the initial treatment, 69 patients (96%) were discharged on oral CSA with mean blood CSA concentrations of 192 +/- 55 ng/mL. Azathioprine was added in 64 (89%) patients. A second treatment with CSA was necessary in 11 patients; 1 patient received three courses of i.v. treatment. The duration of follow-up averaged 773 +/- 369 days. Patients who were responders but were still having certain symptoms at discharge had a higher incidence of colectomy during follow-up. Of all initial responders, 18 (25%) underwent colectomy after a mean interval of 178 +/- 141 days. The life-table predicts that of all treated patients, 55% will avoid a colectomy during a period of 3 years. Complications of CSA treatment were mostly reversible, but 3 patients (3.5%) died of opportunistic infections (1 of Pneumocystis carinii pneumonia and 2 of Aspergillus fumigatus pneumoniae). One patient with anaphylactic shock caused by the CSA solvent was successfully resuscitated. CONCLUSIONS: CSA is an effective treatment of the majority of patients with severe attacks of UC, although the toxicity and even mortality associated with its use necessitates careful evaluation, selection, and follow-up.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00054725-200403000-00002

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 227

Metadata

Authors
Arts, J., D’Haens, G., Zeegers, M., Van Assche, G., Hiele, M., D’Hoore, A., Penninckx, F., Vermeire, S., & Rutgeerts, P.
Venue
Inflammatory Bowel Diseases
Published
2004-03
Volume
10
Issue
2
Pages
73-78
ISSN
1078-0998 (ISSN-L)
OpenAlex
W2048323123
Cited by
227
References
0
FWCI
7.75
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term Outcome of Treatment with Intravenous Cyclosporin in Patients With Severe Ulcerative Colitis. https://app.cochat.ai/papers/10.1097/00054725-200403000-00002
The paper
Arts, J., D’Haens, G., Zeegers, M., Van Assche, G., Hiele, M., D’Hoore, A., Penninckx, F., Vermeire, S., & Rutgeerts, P. (2004). Long-term Outcome of Treatment with Intravenous Cyclosporin in Patients With Severe Ulcerative Colitis. Inflammatory Bowel Diseases. https://doi.org/10.1097/00054725-200403000-00002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.